NCT06112353 Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
| NCT ID | NCT06112353 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of California, Irvine |
| Condition | Intestinal Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 128 participants |
| Start Date | 2024-04-17 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 128 participants in total. It began in 2024-04-17 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery
Eligibility Criteria
Inclusion Criteria: * Age 18 or older * Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission Exclusion Criteria: * Allergy to Rocuronium, Vecuronium, or Sugammadex * Bowel resection surgery requiring an ostomy * No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality * No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin * Creatinine Clearance (CrCl) of less than 30 * Pregnancy * Incapable of providing consent or understanding the research project
Contact & Investigator
Robert R Field, MD
PRINCIPAL INVESTIGATOR
Associate Clinical Professor
Frequently Asked Questions
Who can join the NCT06112353 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intestinal Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06112353 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06112353 currently recruiting?
Yes, NCT06112353 is actively recruiting participants. Contact the research team at whaleyd@hs.uci.edu for enrollment information.
Where is the NCT06112353 trial being conducted?
This trial is being conducted at Orange, United States.
Who is sponsoring the NCT06112353 clinical trial?
NCT06112353 is sponsored by University of California, Irvine. The principal investigator is Robert R Field, MD at Associate Clinical Professor. The trial plans to enroll 128 participants.